Diabetes drug shows promise for weight loss in Real-World study
NCT ID NCT06427083
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is looking at whether enavogliflozin, a diabetes medication, can help people with type 2 diabetes lose weight. Researchers will track 200 adults over 24 weeks in regular doctor visits. The main goal is to see changes in body weight and BMI, along with safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Enavogliflozin (a diabetes drug that helps lower blood sugar and may aid weight loss)
What this could lead to
If successful, this could show that enavogliflozin is a safe and effective option for weight loss in people with type 2 diabetes, potentially improving overall disease management.
What could go wrong
This is an observational registry study, not a controlled trial, so results may be less reliable. Weight loss effects may be modest, and individual results can vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kyung Hee University Medical Center
Seoul, South Korea